VAISHALI
Vaishali Pharma Limited (VAISHALI) Stock Analysis
Vaishali Pharma Limited manufactures pharmaceutical formulations and APIs for domestic and export markets. It supplies tablets, capsules, and injectables across therapeutic areas from WHO-GMP facilities. The company serves generics customers in regulated and semi-regulated countries. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹7.80
-1.39% 1W | -22.70% 52W
Market Cap
102 CR
P/E Ratio
–
52W High
₹11.2
52W Low
₹4.8
Div. Yield
0%
Beta
0.4
50 DMA
₹8.3
200 DMA
₹7.6
Profit Margin
4.1%
Inst. Own.
0%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 33.45 | 24.65 | 26.93 | 22.89 |
| Expenses | 32.06 | 23.09 | 27.13 | 21.40 |
| Operating Profit | 1.39 | 1.56 | -0.20 | 1.49 |
| OPM % | 4.16% | 6.33% | -0.74% | 6.51% |
| Other Income | 0.84 | 0.89 | 1.26 | 0.58 |
| Interest | 0.40 | 0.51 | 0.72 | 0.20 |
| Depreciation | 0.17 | 0.13 | 0.16 | 0.14 |
| Profit before tax | 1.66 | 1.81 | 0.18 | 1.73 |
| Tax % | 28.31% | 28.18% | -61.11% | 13.87% |
| Net Profit | 1.19 | 1.32 | 0.41 | 1.55 |
| EPS in Rs | 0.09 | 0.10 | 0.03 | 0.12 |
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 109 | 108 |
| Expenses | 105 | 104 |
| Operating Profit | 4 | 4 |
| OPM % | 3.8% | 3.9% |
| Other Income | 4 | 4 |
| Interest | 2 | 2 |
| Depreciation | 1 | 1 |
| Profit before tax | 5 | 5 |
| Tax % | 25% | |
| Net Profit | 4 | 4 |
| EPS in Rs | 0.32 | 0.34 |
| Dividend Payout % | 0% |
Shareholding Pattern
Promoters26.32%
Public73.68%
Promoters31.61%
Public68.39%
Promoters31.61%
Public68.39%
Promoters31.61%
Public68.39%
Promoters30.54%
Public69.46%
Promoters26.74%
FIIs0.57%
Public72.69%
Promoters26.32%
Public73.68%
Promoters26.32%
Public73.68%
Promoters31.61%
Public68.39%
Promoters30.54%
Public69.46%
VAISHALI
Holdings Analysis
Key strengths & risk signals
51
Overall
45
Fundamental
58
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 22.7% in the last year.
RECOVERY MODE! Current price (7.8) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 1.4% (1 week), 10.0% (1 month), 0.4% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (8.3) is above 200-day average (7.6) - positive signal.
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
APPROACHING OVERSOLD! RSI at 38.1 - watch for reversal.
Fundamental & Technical Analysis
51Overall
45Fundamental
58Technical
Fundamental Breakdown
Growth Quality
15/30
Revenue CAGR: 18.0% (VERY GOOD, 13/15). Profit CAGR: -15.2% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 4.1% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.19 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 73.26% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (8.3) is above 200-day average (7.6) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (7.8) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
1/10
POOR YEAR! Stock declined 22.7% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 169,376 vs down days: 159,578. Ratio: 1.06x
RSI
4/5
APPROACHING OVERSOLD! RSI at 38.1 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 46.9% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 1.4% (1 week), 10.0% (1 month), 0.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VAISHALI | ₹7.80 | – | 4.1% | 18.0% | -15.2% | -22.7% | 51 | BREAKDOWN | – | +278.0% | – | -15.0% |
| ALPA | ₹53.50 | 31.8 | 3.8% | 4.3% | 6.1% | -34.9% | 47 | BREAKDOWN | -91.5% | -28.6% | +25.1% | -23.9% |
| BALAXI | ₹22.10 | 49.1 | 0.9% | -7.1% | -68.6% | -46.1% | 48 | APPROACHING SUPPORT | +333.3% | +116.7% | +14.1% | +14.1% |
| KREBSBIO | ₹60.20 | – | -55.9% | -23.1% | – | -13.9% | 51 | CONSOLIDATION | -52.8% | +8.7% | +27.3% | +2.9% |
| PAR | ₹109.50 | 10.3 | 13.3% | 11.0% | 1.0% | +8.9% | 52 | BREAKDOWN | +42.7% | +423.3% | +20.3% | +59.6% |
| VIVIMEDLAB | ₹6.60 | – | -231.3% | -27.9% | – | +38.2% | 49 | CONSOLIDATION | +2,526.8% | +786.1% | -53.1% | -25.0% |
| BALPHARMA | ₹95.80 | 21.1 | 2.2% | 0.1% | 34.7% | +21.4% | 71 | CONSOLIDATION | +450.0% | -69.4% | +34.4% | +5.4% |
| MANGALAM | ₹31.10 | – | -16.5% | -14.3% | – | -53.8% | 41 | APPROACHING SUPPORT | -44.9% | -43.3% | -0.2% | -15.2% |
Data from TradeAlone · Updated daily
No news tagged for VAISHALI yet.
